Oral antivirals revisited in the treatment of herpes zoster: What do they accomplish?

American Journal of Clinical Dermatology

Volumn 3, Issue 9, 2002, Pages 591-598

  Nikkels, Arjen F ^b   Piérard, Gérald E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMITRIPTYLINE; ANTIVIRUS AGENT; BROXURIDINE; CORTICOSTEROID; FAMCICLOVIR; PENCICLOVIR; PREDNISOLONE; SORIVUDINE; VALACICLOVIR;

ADULT; AGED; CLINICAL TRIAL; CONJUNCTIVITIS; CORNEA ULCER; DISEASE DURATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; HEALING; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; META ANALYSIS; PAIN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PUBLICATION; PUNCTATE KERATITIS; REVIEW; SIDE EFFECT; SYMPTOM; TREATMENT INDICATION;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; ELIGIBILITY DETERMINATION; FEMALE; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMANS; IMMUNOCOMPROMISED HOST; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 0036909097     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200203090-00001     Document Type: Review

References (90)

1. Grose C. Varicella zoster virus infections: Chickenpox, shingles, and varicella vaccine. In: Glaser R, Jones JF, editors. Herpes Virus Infection. New York: Marcel Dekker Inc. 1994: 1117-85
2. Arvin AM. Varicella zoster virus. In: Fields BN, Knipe DM, Howley PM, et al., editors. Fields Virology. 3rd Ed. Philadelphia (PA): Lippincott-Publishers, 1996: 2547-85
3. Sanders HWA. Herpes Zoster in de Huisartspraktijk [doctoral thesis]. Nijmegen: University of Nijmegen, 1968
4. Dworkin RH, Perkins FM, Nagasako EM. Prospects for the prevention of postherpetic neuralgia in herpes zoster patients. Clin J Pain 2000; 16 (2 Suppl.): S90-100
5. Levin MJ. Vaccination against zoster. Pain Res Clin Manag 2001; 11: 131-42
6. Petursson G, Helgason S, Gudmundsson S, et al. Herpes zoster in children and adolescents. Pediatr Infect Dis J 1998; 17: 905-8
7. Latif R, Shope TC. Herpes zoster in normal and immunocompromised children. Am J Dis Child 1983; 137: 801-2
8. Terada K, Kawano S, Yoshihiro K, et al. Characteristics of herpes zoster in otherwise normal children. Pediatr Infect Dis J 1993; 12: 960-1
9. Kakourou T, Theodoridou M, Mostrou G, et al. Herpes zoster in children. J Am Acad Dermatol 1998; 39: 207-10
10. Harding SP, Porter SM. Oral aciclovir in herpes zoster ophthalmicus. Curr Eye Res 1991: 10: 177-82
11. Cobo ML, Foulks GN, Liesegang TJ, et al. Oral aciclovir in the therapy of acute herpes zoster ophthalmicus. Ophthalmology 1985; 92: 1574-83
12. Cobo M. Reduction of the ocular complications of herpes zoster ophthalmicus by oral acyclovir. Am J Med 1988: 85 Suppl. 2a: 90-3
13. Borruat FX, Buechi ER, Piquet B, et al. Prevention des complications oculaires de l'herpes zoster ophthalmique par un traitement adequat d'acyclovir. Klin Monatsbl Augenheilkd 1991; 198: 358-60
14. Herbort CP, Buechi ER, Piquet B, et al. High-dose oral acyclovir in acute herpes zoster ophthalmicus: The end of the corticosteroid era. Curr Eye Res 1991; 10: 171-5
15. Colin J, Prisant O, Cochener B, et al. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology 2000; 107: 1507-11
16. Balfour Jr HH. Varicella-zoster virus infections in the immunocompromised host: Natural history and treatment. Scand J Infect Dis 1991: 23 Suppl. 80: 69-74
17. Balfour HH. Varicella zoster infections in immunocompromised hosts. Am J Med 1988; 85 Suppl. 2A: 68-73
18. Mandal BK. Herpes zoster and the immunocompromised. J Infect 1987; 14: 15-9
19. Nikkels AF, Delvenne P, Sadzot-Delvaux C, et al. Distribution of varicella zoster virus and herpes simplex virus in disseminated fatal infections. J Clin Pathol 1996; 49: 243-8
20. Han CS, Miller W, Haake R, et al. Varicella zoster infection after bone marrow transplantation: Incidence, risk factors and complications. Bone Marrow Transplant 1994; 13: 277-83
21. Nikkels AF, Snoeck R, Rentier B, et al. Chronic verrucous varicella zoster virus skin lesions: Clinical, histological, molecular and therapeutic aspects. Clin Exp Dermatol 1999; 24: 346-53
22. Nikkels AF, Piérard GE. Recognition and treatment of shingles. Drugs 1994; 48: 528-48
23. O'Brien JJ, Campoli-Richards DM. Acyclovir: An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989; 37: 233-309
24. Wagstaff AJ, Faulds D, Goa KJ. Aciclovir: A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 153-205
25. Perry CM, Faulds D. Valaciclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpes virus infections. Drugs 1996; 52: 754-72
26. Ormrod D, Goa K. Valaciclovir: A review of its use in the management of herpes zoster. Drugs 2000; 59: 1317-40
27. Piérard GE, Nikkels AF. Le médicament du mois: Le valaciclovir (Zelitrex). Rev Med Liege 1997; 52: 553-5
28. Nikkels AF, Piérard GE. Comment je traite: Le zona. Rev Med Liege 1999; 54: 71-5
29. Nikkels AF, Piérard GE. Current therapies for shingles. Exp Opin Invest Drugs 1996; 5: 185-96
30. Perry CM, Wagstaff AJ. Famciclovir: A review of its pharmacological properties and therapeutic efficacy in herpes virus infections. Drugs 1995; 50: 396-415
31. Dworkin RH, Carrington D, Cunningham A, et al. Assessment of pain in herpes zoster: Lessons learned from antiviral trials. Antiviral Res 1997; 33: 73-85
32. Anonymous. A blue print for studies in herpes zoster. Expert Opin Herpes 1994; 7: 1-3
33. Wood MJ, Balfour H, Beutner K, et al. How should zoster trials be conducted? J Antimicrob Chemother 1995; 36: 1089-101
34. Tyring S, Barbarash RA, Nahlik JE, et al. Collaborative famciclovir herpes zoster study group: Famciclovir for the treatment of acute herpes zoster: Effects on acute disease and postherpetic neuralgia. Ann Intern Med 1995; 123: 89-96
35. Kalman CM, Laksin OL. Herpes zoster and zosteriform herpes simplex virus infections in immunocompetent patients. Am J Med 1986; 81: 775-8
36. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of postherpetic neuralgia: A retrospective study in an elderly population. Eur J Pain 1999; 3: 335-42
37. Burgoon CF, Burgoon JS, Baldridge GD. The natural history of herpes zoster. JAMA 1957; 164: 265-9
38. Söltz-Szöts J. Kritische Bemerkungen sur Klinik und Therapie des Herpes Zoster. Zentralbl Haut u Geschlechtskrankheiten 1965; 38: 123-7
39. Helgason S, Petursson G, Gudmundsson S, et al. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: Prospective study with a long term follow up. BMJ 2000; 321: 794-6
40. Helgason S, Sigurdsson JA, Gudmundsson S. The clinical course of herpes zoster: A prospective study in primary care. Eur J Gen Pract 1996; 2: 12-6
41. De Moragas JM, Kierland RR. The outcome of patients with herpes zoster. Arch Dermatol 1957; 75: 193-6
42. Wood MJ, Ogan PH, McKendrick MW, et al. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988; 85: 79-83
43. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989; 102: 93-5
44. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with aciclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39: 1546-53
45. Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of aciclovir for 7 days or 21 days with and without prednisolone for the treatment of acute herpes zoster. N Engl J Med 1994; 330: 896-900
46. Huff JC, Bean B, Balfour HH. et al. Therapy of herpes zoster with oral aciclovir. Am J Med 1988; 85: 84-9
47. Wassilew SW, Reimlinger S, Nasemann T, et al. Oral acyclovir for herpes zoster: A double-blind controlled trial in normal subjects. Br J Dermatol 1987; 117: 495-501
48. Hoang-Xuan T, Buchi EB, Herbort CP, et al. Oral aciclovir for herpes zoster ophthalmicus. Ophthalmology 1992; 99: 1062-71
49. Whithley RJ, Weiss H, Gnann JW, et al. Acyclovir with and without prednisone for the treatment of herpes zoster: A randomized, placebo-controlled trial. Ann Intern Med 1996; 125: 376-83
50. Vander Straten M, Carrasco D, Lee P, et al. Reduction of postherpetic neuralgia in herpes zoster. J Cutan Med Surg 2001; 5: 409-16
51. Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: An overview of clinical trials with aciclovir. Scand J Infect Dis 1991; 23 Suppl. 78: 62-8
52. Wood MJ, Kay R, Dworkin RH, et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: A meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22: 341-7
53. McKendrick MW, Care C, Borke C, et al. Oral aciclovir in herpes zoster. J Antimicrob Chemother 1984; 14: 661-5
54. McKendrick MW, McGill JI, Wood MJ. Lack of effect of acyclovir on postherpetic neuralgia. BMJ 1989; 298: 431
55. Degreef H, and the Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: Results of the first controlled clinical study demonstrating its efficacy and safety in immunocompetent patients. Int J Antimicrob Agents 1994; 4: 241-6
56. Anonymous. Famciclovir safe and effective for management of shingles. AIDS Patient Care STDS 1997; 11: 198
57. Tyring S, Belanger R, Bezwoda W, et al. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001; 19: 13-22
58. Tyring S, Engst R, Corriveau C, et al. Famciclovir for ophthalmic zoster: A randomised aciclovir controlled study. Br J Ophthalmol 2001; 85: 576-81
59. Eaglestein WH, Katz R, Brown JA. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. JAMA 1970; 211: 1681-3
60. Esmann V, Geil JP, Kroon S. et al. Prednisolone does not prevent postherpetic neuralgia. Lancet 1987; 11: 126-9
61. Dworkin RH, Boon RJ, Griffin DRG, et al. Postherpetic neuralgia: Impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis 1998; 178 Suppl. 1: 71-5
62. Whitley RJ, Gnann JW. Herpes zoster: Focus on treatment in older adults. Antiviral Res 1999; 44: 145-54
63. Whitley RJ, Gnann Jr JW, Weiss HL, et al. Unique clinical trial design: Combination acyclovir plus prednisone therapy of localized zoster in the normal host. Antiviral Res 1996; 29: 67-8
64. Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: Randomized, controlled clinical trial of valaciclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000; 9: 863-9
65. Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997; 157: 1217-24
66. Alper BS, Lewis PR. Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? J Fam Pract 2000; 49: 255-64
67. Johnson R. Herpes zoster-predicting and minimizing the impact of post-herpetic neuralgia. J Antimicrob Chemother 2001; 47 Suppl. 1: 1-8
68. Wacker P, Hartmann O, Benhamou E, et al. Varicella zoster virus infections after autologous bone marrow transplantation in children. Bone Marrow Transplant 1989; 4: 191-4
69. Perren RJ, Powles RL, Easton D, et al. Prevention of herpes zoster in patients by long term oral acyclovir after allogenic bone marrow transplantation. Am J Med 1988; 85 Suppl. 2A: 99-101
70. Van Den Broek PJ, Van Der Meer JW, Mulder JD, et al. Limited value of acyclovir in the treatment of uncomplicated herpes zoster: A placebo controlled study. Infection 1984; 12: 338-41
71. Marshall T. Postherpetic neuralgia: Treatment with amitriptyline is cheaper than with aciclovir. BMJ 2001; 322: 860-1
72. Whitley RJ, Gnann Jr JW, Hinthorn D, et al. Disseminated herpes zoster in the immunocompromised host: A comparative trial of acyclovir and vidarabine. J Infect Dis 1992; 165: 450-5
73. Meyers JD. Treatment of the varicella zoster infections in immunocompromised patients. Res Clin Forums 1986; 9: 65-74
74. Peterslund NA. The treatment of herpes zoster infections. Stand J Infect Dis 1985; 17 Suppl. 47: 80-4
75. Petterson E, Hovi T, Ahonen J, et al. Prophylactic oral aciclovir after renal transplantation. Transplantation 1985; 39: 279-81
76. Masaoka T, Hiraoka A, Teshima H, et al. Varicella zoster infection in immunocompromised patients. J Med Virol 1993; Suppl. 1: 82-4
77. Levin MJ, Zaia JA, Hershey BJ, et al. Topical acyclovir treatment of herpes zoster in immunocompromised patients. J Am Acad Dermatol 1985; 13: 590-6
78. Rothe MJ, Feder Jr HM, Grant-Kels JM. Oral acyclovir therapy for varicella and zoster infections in pediatric and pregnant patients: A brief review. Pediatr Dermatol 1991; 8: 236-7
79. Sempere A, Sanz GF, Senent L, et al. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia. Bone Marrow Transplant 1992; 10: 495-8
80. Ljungman P, Lonnquist B, Ringden O, et al. A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Bone Marrow Transplant 1989; 4: 613-5
81. Ladriere M, Bibes B, Rabaud C. et al. Varicella zoster virus infection after bone marrow transplant: Unusual presentation and importance of prevention. Presse Med 2001; 30: 1151-4
82. Yagi T, Karasuno T, Hasegawa T, et al. Acute abdomen without cutaneous signs of varicella zoster virus infection as a late complication of allogeneic bone marrow transplantation: Importance of empiric therapy with acyclovir. Bone Marrow Transplant 2000; 25: 1003-5
83. Stemmer SM, Kinsman K, Tellschow S, et al. Fatal noncutaneous visceral infection with varicella-zoster virus in a patient with autologous bone marrow tranplantation. Clin Inf Dis 1993; 16: 497-9
84. Novelli VM, Marshall WC, Yeo J. et al. Acyclovir administered perorally in immunocompromised children with varicella zoster infections. J Infect Dis 1984; 149: 478
85. Höglund M, Ljungman P, Weller S. Comparable aciclovir exposures produced by oral aciclovir in immunocompromised cancer patients. J Antimicrob Chemother 2001; 47: 855-61
86. Bomgaars L, Duran C, Khan S, et al. The pharmacokinetics of valaciclovir in immunocompromised children [abstract]. Clin Pharmcol Ther 2000; 69: P158
87. Levin MJ. Use of varicella vaccines to prevent herpes zoster in older individuals. Arch Virol 2001; 146 Suppl. 17: 151-60
88. Straus SE. Varicella-zoster virus immunity and prevention: A conference perspective. Arch Virol 2001; 146 Suppl. 17: 173-8
89. Takahashi M, Kamiya H, Asano Y, et al. Immunization of the elderly to boost immunity against varicella-zoster virus (VZV) as assessed by VZV skin test reaction. Arch Virol 2001: 146 Suppl. 17: 161-72
90. Gershon AA. The current status of live attenuated varicella vaccine. Arch Virol 2001; 146 Suppl. 17: 1-6